소아청소년에서 편두통 치료 약물 처방 현황

유기연 한국임상약학회 2022 한국임상약학회지 Vol.32 No.3

Background: Migraine is one of the leading causes of poor quality of life and disability, and migraine incidences in pediatrics areincreasing. Proper medication is important for the preventive and acute treatment of migraine. This study aimed to identify thecurrent status of prescribed medication in pediatric patients with migraine. Methods: We used data from a sample of pediatric patientsfrom the Health Insurance Review and Assessment Service (HIRA-PPS-2018) and analyzed the status of prescription drugs andfrequency of visits to medical institutions with migraine diagnoses in pediatric patients. Results: A total of 12,228 pediatric patientsdiagnosed with migraine during 2018 were analyzed. Among these patients, 7,170 (58.64%) were girls and 9,510 (77.77%) wereadolescents. Additionally, 9,157 patients (74.89%) received acute treatment, and 592 patients (4.84%) received combination therapywith analgesics and triptans. Acetaminophen for acute treatment and flunarizine for preventive treatment were the most commonlyprescribed. In most children and adolescents, acute treatment drugs were prescribed for less than 14 days. Conclusion: Analgesics,such as acetaminophen or non-steroidal anti-inflammatory drugs, were prescribed frequently for acute treatment in pediatric patientswith migraine. The drug prescription duration was within the recommended range, indicating a low risk of overdose. For preventivetreatment, clinically studied medication for pediatric patients with migraine was used.

사람과 건축 이야기 - 과거를 회상하며

유기연,Yu, Kiyeon 대한건축사협회 2023 建築士 Vol.654 No.-

Berberry extract reduces neuronal damage and N-methyl-D-aspartate receptors immunoreactivities in the gerbil hippocampus after transient forebrain ischemia

유기연,황인구,이승욱,임병우,강태천,김동우,김상무,이현용,김종대,원무호 한국실험동물학회 2005 한국실험동물학회 학술발표대회 논문집 Vol.2005 No.-

만성골수성백혈병 치료제의 효과: 메타분석

유기연 한국병원약사회 2013 병원약사회지 Vol.30 No.4

Chronic myeloid leukemia (CML) is one of the myeloproliferative disorders which is associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in a BCR-ABL gene. This abnormal gene produces a specific product BCR-ABL tyrosine kinase. Therefore, tyrosine kinase inhibitors (TKIs) could be used for long term controls of CML progression for most patients, and these have good tolerance and low adverse drug reaction rates. The present study was performed to evaluate the efficacy and safety of imatinib, dasatinib, and nilotinib as a first, second, third line therapy for CML. This meta-analysis was taken on August 31st 2012, the Medline and Embase searches were used to access the appropriate studies. Twenty-six studies, which suggested the cytogenetic, hematologic and molecular responses, were selected for this analysis. Dasatinib (0.839, 95% CI: 0.790-0.878) and nilotinib (0.797, 95% CI: 0.749-0.838) were analyzed as to having superior cytogenetic responses for patients of newly diagnosed CML-CP (chronic phase) when compared to imatinib (0.676, 95% CI: 0.749-0.838). The ADR, however were less shown in the imatinib group as compared to the second generation TKIs. For imatinib resistant or intolerant patients, the dasatinib 100 mg qd (CCgR 95% CI: 0.474-0.597, CHR 95% CI: 0.877-0.953, MMolR 95% CI: 0.253-0.376) were analyzed with the most suitable therapy option as compared to dasatinib 70 mg (CCgR 95% CI: 0.372-0.429, CHR 95% CI: 0.489-0.561, MMolR 95% CI: 0.274-0.410) or nilotinib 400 mg bid (CCgR 95% CI: 0.324-0.382, CHR 95% CI: 0.587-0.673, MMolR 95% CI: 0.220-0.289). In the third line therapy for CML, there are no significant differences between dasatinib 70 mg bid and nilotinib 400 mg bid groups.

류마티스관절염 환자의 심혈관 질환 및 당뇨병 위험분석: a propensity score analysis

유기연 한국임상약학회 2019 한국임상약학회지 Vol.29 No.2

Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests as joint damage or athletic disability via sustained inflammation of the synovial membrane. The risk of cardiovascular disease (CVD) is higher in RA patients. This study aimed at evaluating the association between CVD comorbidities and RA by comparing a pharmacotherapy group with a nonpharmacotherapy group. Methods: Patient sample data from the Health Insurance Review and Assessment Service (HIRA-NPS- 2016) were used. Inverse probability of treatment weighting (IPTW) using the propensity score was used to minimize the differences in patient characteristics. Logistic regression analysis was used to evaluate the risk of CVD comorbidities. Results: The analyses included 1,207,213 patients, of which 33,122 (2.8%) had RA. The odds ratios (OR) of CVD comorbidities were increased in RA patients; ischemic heart disease (IHD: OR 1.75; 95% CI 1.73, 1.77), cerebral infarction (CERI: OR 1.28; 95% CI 1.26, 1.30), hypertension (HTN: OR 1.44; 95% CI 1.43, 1.45), diabetes mellitus (DM: OR 2.04; 95% CI 2.03, 2.06), and dyslipidemia (DL: OR 3.49; 95% CI 3.47, 3.51). The ORs of IHD, CERI, HTN, and DM in the traditional DMARD and biologic treatment groups were decreased, compared with those in the non-pharmacotherapy group. Conclusions: Thus, CVD risk was higher in RA patients, considering age, sex, and socioeconomic status. Appropriate pharmacotherapy could decrease the risk of CVD comorbidities in RA patients.

식품의약품안전청에 보고된 심혈관계 약물유해반응의 특성 분석

유기연,조혜경,이숙향 한국임상약학회 2012 한국임상약학회지 Vol.22 No.1

치매환자에서의 심혈관계 약물사용 분석

유기연 한국임상약학회 2017 한국임상약학회지 Vol.27 No.3

Background: Dementia is one of important social and economic healthcare issues in the aging age. Therefore, it signifies to analyze the relationship between chronic disease or cardiovascular drug use and the incidence of dementia to establish a basis for increasing or preventing the risk of dementia. The purpose of this study was to investigate the correlation between the prevalence of chronic diseases and the use of cardiovascular drugs in patients diagnosed with dementia. Methods: In this study, we used data from sample of elderly patients from the Health Insurance Review and Assessment Service. We analyzed by logistic regression analysis with age, gender, and medication as covariates. KCD-7 was used to diagnosis of the disease, and drugs were analyzed using ATC codes and Korean standardized drug classification codes. Results: A total of 1,276,331 patients were analyzed in the sample of the elderly population, of which 532,075 (41.7%) were male and 744,256 (58.3%) were female. The patients have the higher risk of dementia in the older, women, and lower socioeconomically status. Cerebral infarction and ischemic heart disease increases risk of dementia. Patients taking statins, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonists (ARB) showed low incidence of dementia. Conclusion: This study has been shown that ACEI, ARB, and statin drugs may associate with lower incidence of Alzheimer's and other dementia except vascular dementia.

Copper chaperone for Cu,Zn-SOD supplement potentates the Cu,Zn-SOD functions of neuroprotective effects against ischemic neuronal damage in the gerbil hippocampus

유기연,음원식,김대원,이승욱,이윤희,강태천,권오신,강정훈,최수영,원무호 한국실험동물학회 2005 한국실험동물학회 학술발표대회 논문집 Vol.2005 No.-

덱스라족산의 두 가지 다른 용량의 비교 연구

유기연 한국임상약학회 2010 한국임상약학회지 Vol.20 No.3

본 연구에서는 anthracyclines의 심장 독성을 예방하기 위해 사용되는 dexrazoxane의 가장 적절하고 안전한 용량을 평가하고자 했다. 이 약물은 같은 적응증에도 불구하고 미국과 유럽에서 두 배 차이가 나는 용량으로 허가 받아 사용되고있다. 그러므로 dexrazoxane의 anthracycline로 인한 심독성의 예방에 관한 논문을 찾아 dexrazoxane : doxorubicin = 20: 1의 비율로 사용했을 경우와 10:1로 사용했을 때의 효과와 부작용을 비교 하였다. 이 두 가지 용량으로 진행된 모든 임상 연구에서 dexrazoxane이 doxorubicin의 심독성 예방에 통계적으로 유효한 효과가 있다고 결론 내렸다. 또한 dexrazoxane의 추가 요법으로 인해 Tumor effect의 차이를 비교 분석한 결과, 두 가지 용량 모두에서 dexrazoxane이 doxorubicin의 항암 효과에 영향을 미치지 않는 것으로 분석되었다. 대부분의 연구에서 dexrazoxane의 약물 자체의 부작용은 분석하지 않았지만, dexrazoxane:doxorubicin을 20:1의 비율로 사용했던 한 연구에서 dexrazoxane군에서 부작용이 있음이 평가되었다. 반면, dexrazoxane의 용량을 doxorubicin 용량에 비해 10:1로 사용한 모든 연구는, 대상 환자군이18세 이하의 소아 청소년으로 이 용량을 성인에게도 적용할 수 있는지에 대한 추가 연구가 필요하다. 그러나 항암제의 경우, 대부분 환자의 체표면적(BSA)을 기준으로 약용량을 결정하며, 이는 일반적으로 10세 이상이 되면 어른의 체표면적 의 70% 정도가 된다. 그러므로, 본 연구에서는 통계적으로 충분한 수의 10세 이상의 소아, 청소년에게 doxorubicin으로 인한 심독성 예방 효과가 입증되었던 dexrazoxane: doxorubicin을 10:1의 용량으로 사용하여도 임상적인 효과를 기대 할 수 있으며, 이 용량은 dexrazoxane 자체의 유해반응도 감소시킬 수 있을 것이라고 결론 맺는다.

Immunoadjuvant Activity of Icariin that Induces Th1-Type Antibody in Mice

유기연,한용문 대한약학회 2012 Archives of Pharmacal Research Vol.35 No.9

The adjuvant effect of icariin from Epimedium koreanum on the immune responses to bovine serum albumin (BSA) in mice was examined. Mice were immunized on days 1 and 22 intraperitoneally (i.p.) with one of the following: an emulsion form of BSA mixed with Incomplete Freund’s Adjuvant (BSA/IFA) or with Complete Freund’s Adjuvant (BSA/CFA) or BSA plus icariin mixed with IFA (BSA/Icariin/IFA). One week after the booster, polyclonal sera were collected from these animals to determine IgG isotypes specific for BSA in the sera and then spleens of these animals were harvested to evaluate IFN-γ and IL-4 produced in the splenocyte cultures. In order to determine the DTH (delayed type hypersensitivity) response, BSA was administered into the footpads of mice that were immunized as described above and the degree of footpad-swelling was measured. Data from these experiments showed that the icariin combined with BSA (BSA/Icariin/IFA) provoked the most abundant of IgG production in mice and enhanced the Th1-lineage development of IgG2a and IFN-γ productions (p < 0.05), whereas BSA/IFA resulted in a highest ratio of IgG1 to IgG2 and most dominant IL-4 production, indicating a Th2 response. This pattern of immunity was confirmed by the DTH determination revealing that icariin-containing formula caused the highest footpad-swelling followed by BSA/CFA and BSA/IFA, respectively. In addition, hemolytic assay showed that icariin at a dose of 1000 μg/mL caused no hemolysis when compared with a water-treated mouse. All of these data indicate that icariin has the immunoadjuvant effect which may enhance Th1-immune response, suggesting that icariin as an adjuvant would be beneficial in the treatment of Th1-disordered diseases.